TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS

1 . An agent comprising:

an antibody moiety or antibody binding moiety,

a target binding moiety, and

optionally a linker moiety linking the antibody moiety and the target binding moiety,

wherein the agent has the structure of formula M-II:

or a pharmaceutically acceptable salt thereof, wherein:

each of a and b is 1,

each AT is an antibody moiety or antibody binding moiety;

L is a linker moiety, and

the antibody moiety or antibody binding moiety comprises

(i) an antibody or a fragment thereof from an IVIG preparation; or

(ii)

 is chosen from A-1 to A-50 as shown in Table A-1.

2 . (canceled)

3 . The agent of claim 1 , wherein the antibody moiety comprises IgG1 or a fragment thereof, IgG2 or a fragment thereof, or IgG4 or a fragment thereof.

4 . The agent of claim 3 , wherein the antibody moiety comprises IgG1 or a fragment thereof linked to the linker L an amino acid residue selected from K246 and K248 of an IgG1 heavy chain and amino acid residues corresponding thereto; or

the antibody moiety comprises IgG2 or a fragment thereof IgG2 or a fragment thereof is linked to the linker, at an amino acid residue selected from K251 and K253 of an IgG2 heavy chain and amino acid residues corresponding thereto; or

the antibody moiety comprises IgG4 or a fragment thereof is linked to the linker, at an amino acid residue selected from K239 and K241 of an IgG4 heavy chain and amino acid residues corresponding thereto.

5 . The agent of claim 4 , wherein L is a covalent bond, or a bivalent or polyvalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic, aryl, heteroaromatic having 1-20 heteroatoms, or any combinations thereof, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or —[(—O—C(R′) 2 —C(R′) 2 —) n ]—, wherein n is 1-20;

Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R;

each R is independently —H, or an optionally substituted.

6 . The agent of claim 4 , wherein the linker comprises one or more —[(CH 2 )n-O]m-, wherein each n is independently 1-20, and m is 1-100.

7 . The agent of claim 6 , additionally comprising a reactive group, RG, bound to the linker group, where RG is a group of the formula -L LG2 , -L LG2 -L LG3 -L LG4 -L RG1 - or -L RG1 -L RG2 -, where

L LG2 is —NH—, —NHC(O)—, —(CH 2 )n-NHC(O)—, —(CH 2 )n-OC(O)—, —(CH 2 )n-OC(O)NH—, —C(O)—NHCH 2 —, —C(O)—NHCH 2 CH 2 —, —C(O)O—CH 2 —, or NH—C(O)O—CH 2 —;

L LG3 is an optionally substituted aryl ring;

L LG4− is a bond, —NH— or —O—;

L RG1 is —O—C(O)—, —CO)—, —S(O)— —OS(O) 2 —, or —OP(O(OR)—;

L RG2 is —CH 2 —C(O)—, —C(O)— or —CH 2 —;

L LG is —(O)C—[(CH 2 )nO]m(CH 2 )nNH—, —(O)C—[(CH 2 )nO]m(CH 2 )nNH—, —[(CH 2 )nO]mNHC(O)[(CH 2 )nO]mNH—, —[(CH 2 )nO]m{NHC(O)[(CH 2 )nO]m}pNH—, —[(CH 2 )nO]mCy [(CH 2 )nO]mNH, —[(CH 2 )nO]mCy [(CH 2 )nO]mNH C(O)[(CH 2 )nO]mNH—, or —[(CH 2 )nO]mCy [(CH 2 )nO]m{NH C(O)[(CH 2 )nO]m}pNH—,

where n, m, and p are integers independently chosen at each occurrence from 1-12, and Cy is an optionally substituted cyclic group.

8 . The agent of claim 7 , wherein RG is a group of the formula -L LG2 -L LG3 -L LG4 -L RG1 and is selected from:

9 - 12 . (canceled)

13 . The agent of comprises a reactive group, wherein upon contact with an antibody, the reactive group reacts with a group of the antibody and conjugates a target binding moiety, or a moiety comprising -(Xaa)y-, to the antibody optionally through a linker, where -(Xaa)y is a peptide having at least 90% sequence homology to one of the following sequences:

(SEQ ID NO: 1)

DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFE

LAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR,

(SEQ ID NO: 2)

ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKS

DDEREIREIEEEARRILEHLEELARK,

(SEQ ID NO: 3)

DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 4)

DKEEILNKIYEIMRLLDELGNAEASMRVSDLILEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 5)

SDDEDSVRYLLYMAELRYEQGNPEKAKKILEMAEFIAKRNNNEELERLV

REVKKRL,

(SEQ ID NO: 6)

NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLE

KVVEELKELLERLLS,

(SEQ ID NO: 7)

QREKRLKQLEMLLEYAIERNDPYLMFDVAVEMLRLAEENNDERIIERAK

RILEEYE,

(SEQ ID NO: 8)

SLEELKEQVKELKKELSPEMRRLIEEALRFLEEGNPAMAMMVLSDLVYQ

LGDPRVIDLYMLVTKT,

(SEQ ID NO: 9)

DREQRLVRFLVRLASKFNLSPEQILQLFEVLEELLERGVSEEEIRKQLE

EVAKELG,

(SEQ ID NO: 10)

DDDIRYLIYMAKLRLEQGNPEEAEKVLEMARFLAERLGMEELLKEVREL

LRKIEELR,

and

(SEQ ID NO: 11)

PIIELLREAKEKNDEFAISDALYLVNELLQRTGDPRLEEVLYLIWRALK

EKDPRLLDRAIELFER.

14 . (canceled)

15 . The agent of claim 7 , wherein the reactive group is or comprises

wherein —C(O)— is connected to a target binding moiety, or a moiety comprising -(Xaa)y-, optionally through a linker.

16 . (canceled)

17 . An agent, wherein the agent has the structure of formula R-I:

LG-RG-L RM -MOI,   (R-I)

or a salt thereof, wherein:

LG is R LG -L LG ;

R LG is

R c -(Xaa)z-, IVIG, a nucleic acid moiety, or a small molecule moiety;

each Xaa is independently a residue of an amino acid or an amino acid analog;

t is 0-50;

z is 1-50;

each R c is independently -L a -R′;

each of a and b is independently 1-200;

each L a is independently a covalent bond, or an optionally substituted bivalent group selected from C 1 -C 20 aliphatic or C 1 -C 20 heteroaliphatic having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C(R′) 2 —, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, or —C(O)O—;

each -Cy- is independently an optionally substituted bivalent monocyclic, bicyclic or polycyclic group wherein each monocyclic ring is independently selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms;

L LG is -L LG1 -, -L LG1 -L LG2 -, -L LG1 -L LG2 -L LG3 -, or -L LG1 -L LG2 -L LG3 -L LG4 -;

RG is -L RG1 -L RG2 -, -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -L RG1 -L RG2 -, -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -;

each of L LG1 , L LG2 , L LG3 , L LG4 , L RG1 , L RG2 , and L RM is independently L;

each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched C 1-100 group comprising one or more aliphatic moieties, aryl moieties, heteroaliphatic moieties each independently having 1-20 heteroatoms, heteroaromatic moieties each independently having 1-20 heteroatoms, or any combinations of any one or more of such moieties, wherein one or more methylene units of the group are optionally and independently replaced with C 1-6 alkylene, C 1-6 alkenylene, a bivalent C 1-6 heteroaliphatic group having 1-5 heteroatoms, —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or —[(—O—C(R′) 2 —C(R′) 2 —)n]—, wherein n is 1-20;

each R′ is independently —R, —C(O)R, —CO 2 R, or —SO 2 R;

each R is independently —H, or an optionally substituted group selected from C 1-30 aliphatic, C 1-30 heteroaliphatic having 1-10 heteroatoms, C 6-30 aryl, C 6-30 arylaliphatic, C 6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms; and

MOI is peptide having at least 90% identity with a sequence selected from:

(SEQ ID NO: 1)

DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFE

LAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR,

(SEQ ID NO: 2)

ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKS

DDEREIREIEEEARRILEHLEELARK,

(SEQ ID NO: 3)

DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 4)

DKEEILNKIYEIMRLLDELGNAEASMRVSDLILEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 5)

SDDEDSVRYLLYMAELRYEQGNPEKAKKILEMAEFIAKRNNNEELERLV

REVKKRL,

(SEQ ID NO: 6)

NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLE

KVVEELKELLERLLS,

(SEQ ID NO: 7)

QREKRLKQLEMLLEYAIERNDPYLMFDVAVEMLRLAEENNDERIIERAK

RILEEYE,

(SEQ ID NO: 8)

SLEELKEQVKELKKELSPEMRRLIEEALRFLEEGNPAMAMMVLSDLVYQ

LGDPRVIDLYMLVTKT,

(SEQ ID NO: 9)

DREQRLVRFLVRLASKFNLSPEQILQLFEVLEELLERGVSEEEIRKQLE

EVAKELG,

(SEQ ID NO: 10)

DDDIRYLIYMAKLRLEQGNPEEAEKVLEMARFLAERLGMEELLKEVREL

LRKIEELR,

and

(SEQ ID NO: 11)

PIIELLREAKEKNDEFAISDALYLVNELLQRTGDPRLEEVLYLIWRALK

EKDPRLLDRAIELFER.

18 . The agent of claim 17 , wherein the antibody binding moiety comprises or has the structure of

(i) DCAWHLGELVWCT (SEQ ID NO:35) or a salt form thereof, wherein the two C residues are linked by a —S—S—;

(ii) DCAWHLGELVWCT (SEQ ID NO:35) or a salt form thereof, wherein the N-terminus is capped with R—C(O)—; or

(iii) DCAWHLGELVWCT (SEQ ID NO:35) or a salt form thereof, wherein the N-terminus is capped with R—C(O)—, wherein R is methyl;

(iv) DCAWHLGELVWCT (SEQ ID NO:35) or a salt form thereof, wherein the antibody binding moiety is connected to the rest of a molecule through its C-terminus.

19 . The agent of claim 17 , wherein the antibody binding moiety comprises or has the structure selected from A-1 to A-50, or a salt form thereof:

20 . The agent of claim 1 , wherein each L is independently a covalent bond, or a bivalent optionally substituted, linear or branched aliphatic group or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with —C≡C—, -Cy-, —C(R′) 2 —, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —C(O)C(R′) 2 N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, an amino acid residue, or —[(—O—C(R′) 2 —C(R′) 2 —) n ]—, wherein n is 1-20.

21 . The agent of claim 17 , wherein

(LG is R LG -L LG -, wherein R LG is or comprises a target binding moiety and L LG is L LG1 , L LG1 -L LG2 -, L LG1 -L LG2 -L LG3 -, or L LG1 -L LG2 -L LG3 -L LG4 -, where each L LG is independently chosen from L.

22 . The agent of claim 17 , wherein RG is or comprises -L LG2 -L LG3 -L LG4 -L RG1 -L RG1 , -L LG2 -L LG3 -L LG4 -L RG1 -L RG2 -, -L LG3 -L LG4 -L RG1 -L RG2 -, L LG4 -L RG1 -L RG2 -, or -L RG1 -L RG2 -, where

L LG1 is a covalent bond, —(CH 2 CH 2 O)n-, or —(CH 2 )n-O—(CH 2 CH 2 O)n-(CH 2 )n-;

L LG2 is or comprises a covalent bond, —NR′—, —C(O)—, —NR′C(O)—, —(CH 2 )n-OC(O)N(R′)—, —CH 2 N(CH 2 CH 2 CH 2 S(O) 2 OH)—C(O)—, —C(O)—NHCH 2 —, —C(O)O—CH 2 —, or —NH—C(O)O—CH 2 —; R′ is H or C 1 -C 6 alkyl;

L LG3 is optionally bonded to —C(O)— and L LG3 a covalent bond or a substituted phenyl ring, substituted with one or more substituents, and one or more substituents are independently an electron-withdrawing group;

L LG3 is

 where R S is F or NO 2 ;

L LG4 is a covalent bond, —O—, —NR′—;

L RG1 is a covalent bond, —S(O) 2 — or —C(O)—;

L RG2 is or comprises —C(O)—, —C(O)O—, —C(O)N(R′)—, —S(O)—, —S(O) 2 —, —P(O)(OR′)—, —P(O)(SR′)—, or —P(O)(N(R′) 2 )—;

wherein each n is independently 1-10, and each —CH 2 — is independently optionally substituted.

23 - 24 . (canceled)

25 . The agent of claim 19 , wherein -L LG2 -L LG3 -L LG4 -L RG1 - is a structure selected from:

26 . The agent of claim 1 , wherein the target binding moiety binds to a SARS-CoV-2 virus particle, such as a protein of a SARS-CoV-2 virus, such as a spike protein of a SARS-Co-V-2 virus, such as spike protein or a fragment thereof of a SARS-CoV-2 virus expressed by an infected cell, or such as SARS-CoV-2 spike receptor binding domain.

27 - 30 . (canceled)

31 . A method of treating SARS-CoV-2 in a mammal comprising administering to the mammal a concentration of the agent of claim 1 sufficient to agent of any one of the provides long term immunity to SARS-CoV-2 to the mammal.

32 . (canceled)

33 . A composition comprising a plurality of agents, wherein each agent independently comprises:

an antibody moiety,

a target binding moiety, and

optionally a linker moiety linking an antibody binding moiety and a target binding moiety, wherein the agents of the plurality share the same antibody moiety, linker moiety, and target binding moiety;

wherein the target binding moiety is a peptide having at least 90% identify with a sequence selected from:

(SEQ ID NO: 1)

DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFE

LAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR,

(SEQ ID NO: 2)

ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKS

DDEREIREIEEEARRILEHLEELARK,

(SEQ ID NO: 3)

DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 4)

DKEEILNKIYEIMRLLDELGNAEASMRVSDLILEFMKKGDERLLEEAER

LLEEVER,

(SEQ ID NO: 5)

SDDEDSVRYLLYMAELRYEQGNPEKAKKILEMAEFIAKRNNNEELERLV

REVKKRL,

(SEQ ID NO: 6)

NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLE

KVVEELKELLERLLS,

(SEQ ID NO: 7)

QREKRLKQLEMLLEYAIERNDPYLMFDVAVEMLRLAEENNDERIIERAK

RILEEYE,

(SEQ ID NO: 8)

SLEELKEQVKELKKELSPEMRRLIEEALRFLEEGNPAMAMMVLSDLVYQ

LGDPRVIDLYMLVTKT,

(SEQ ID NO: 9)

DREQRLVRFLVRLASKFNLSPEQILQLFEVLEELLERGVSEEEIRKQLE

EVAKELG,

(SEQ ID NO: 10)

DDDIRYLIYMAKLRLEQGNPEEAEKVLEMARFLAERLGMEELLKEVREL

LRKIEELR,

and

(SEQ ID NO: 11)

PIIELLREAKEKNDEFAISDALYLVNELLQRTGDPRLEEVLYLIWRALK

EKDPRLLDRAIELFER;

and

the antibody comprises IgG1, IgG2, IgG4, an Fc region, or a fragment of any of the foregoing.

34 - 36 . (canceled)

37 . The composition of claim 33 , wherein one or more agents of the plurality can each independently interact hFcγRIIIA.

38 - 41 . (canceled)

42 . The agent of claim 1 , where the agent is selected from